Cytosorbents (CTSO) Short term Debt (2016 - 2026)

Cytosorbents' (CTSO) quarterly Short term Debt came in at $14.1 million in Q2 2026, up 112.89% quarter-over-quarter from $6.6 million in Q1 2026.

Analysis

Cytosorbents (CTSO) Short term Debt (2016 - 2026) Analysis & Trends

Cytosorbents (CTSO) has reported Short term Debt for 8 consecutive years, with $14.1 million the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, Short term Debt changed N/A year-over-year to $14.1 million; the trailing twelve-month figure through Jun 2026 stood at $14.1 million (changed N/A YoY), and the FY2023 full-year result was $2.5 million, changed N/A from the prior year.
Short term Debt rose to $14.1 million in Q2 2026 per CTSO's latest filing, from $6.6 million in the prior quarter.
Across five years, Short term Debt topped out at $14.1 million in Q2 2026 and bottomed at $833333.0 in Q3 2023.
Historically, Short term Debt has averaged $5.3 million across 3 years, with a median of $2.5 million in 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.04 Bn	177.44 Bn	7.27 Bn
2	Intuitive Surgical	125.02 Bn	119.81 Bn	1.96 Bn
3	Medtronic	117.84 Bn	109.02 Bn	6.34 Bn
4	Stryker	105.50 Bn	102.02 Bn	4.50 Bn
5	Boston Scientific	66.27 Bn	65.73 Bn	3.85 Bn
6	Edwards Lifesciences	49.60 Bn	45.35 Bn	1.35 Bn
7	Alcon	33.70 Bn	32.24 Bn	1.68 Bn
8	Dexcom	32.06 Bn	30.11 Bn	830.00 Mn
9	Steris	21.02 Bn	20.54 Bn	684.20 Mn
10	Cytosorbents	20.00 Mn	15.59 Mn	7.05 Mn

Historic Data

Download Data